【百济神州:百泽安在美国获批用于晚期食管鳞状细胞癌联合化疗的一线治疗】3月4日,百济神州宣布,美国食品药品监督管理局已批准百泽安®联合含铂化疗用于肿瘤表达PD-L1的不可切除或转移性食管鳞状细胞癌成人患者一线治疗。百泽安®已在美国获批作为单药用于治疗既往接受过系统化疗后不可切除或转移性ESCC的成人患者,以及联合化疗用于胃和胃食管结合部癌成人患者的一线治疗。

金融界
05 Mar
3月4日,百济神州宣布,美国食品药品监督管理局已批准百泽安®联合含铂化疗用于肿瘤表达PD-L1的不可切除或转移性食管鳞状细胞癌成人患者一线治疗。百泽安®已在美国获批作为单药用于治疗既往接受过系统化疗后不可切除或转移性ESCC的成人患者,以及联合化疗用于胃和胃食管结合部癌成人患者的一线治疗。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10